Some proportions of populations, such as immunocompromised patients and organ
transplant recipients might have inadequate immune responses to the vaccine for …

Background Outpatient monoclonal antibodies are no longer effective and antiviral
treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in …

Until now, the treatment protocols for COVID‐19 have been revised multiple times. The use
and approval of therapeutic monoclonal antibodies (mAbs) for COVID‐19 treatment …

The vaccine weapon has resulted in being essential in fighting the COVID-19 outbreak, but it
is not fully preventing infection due to an alarming spreading of several identified variants of …

Little is known about cardiovascular safety profiles for monoclonal antibody products that
received the FDA Emergency Use Authorization for COVID-19. In this study, data from the …

While mortality caused by sepsis remains an unsolved problem, studies showed conflicting
results about effectiveness of monoclonal and polyclonal antibodies in patients suffering …

Measurement of antibody content and function after a viral illness is important for diagnosis
and selection of the best convalescent plasma (CP) units for passive immunization. Zhang et …

Background The advantages and disadvantages of casirivimab-imdevimab for coronavirus
disease 2019 are not well understood. We conducted a systematic review and meta …

Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a
monoclonal antibody, against Omicron BA. 2 subvariant. However, limited in vivo data exist …

Background & Aims: Molnupiravir is an oral antiviral drug which is used in the treatment of
patients with COVID-19. The purpose of this study was to investigate the effectiveness and …